Fountain Report Excerpts Jan 23, 2024

Fountain Report Excerpts
  1. Virbac reported fourth quarter 2023 revenue of 321.7 million euros, up 9.1% from the same period in 2022. For the year, revenue of 1.25 billion euros was up 2.5% and up 4.9% at constant exchange rates. In terms of species, despite a drop in sales on dog and cat vaccine range (which was out of stock throughout the year) and a decline in parasiticides, the companion animal segment grew 3.5% at constant rates, driven by the performance of pet food, specialties and dermatology ranges. The farm animal segment saw growth of 6.7% at constant rates, driven by both ruminants (up 7.8% at constant rates) and pigs (up 13.1% at constant rates).
  1. Hanover College, a private school of 1,157 students in southern Indiana, is the latest to unveil plans for a veterinary college, bringing the number of emerging veterinary schools in the United States to 12, the VIN News Service reports. If all goes as expected, Indiana will be home to two veterinary schools when Hanover opens in 2026 with at least 80 seats. The other is at Purdue University in West Lafayette. The combined efforts of both programs could more than double the annual graduation count of veterinary students in the state. Purdue, with its usual yearly graduation of 84 students, has recently expanded its teaching hospital and now can accommodate 120 students. Moving forward requires approval from the AVMA Council on Education, the nation’s accrediting authority for veterinary schools. Hanover has initiated the accreditation process by requesting a consultative site visit.
  1. A new bill filed in the Florida Legislature would allow xylazine to once again be administered to animals in the state, The Floridian reports. The legislation would remove xylazine animal drug products from the list of Schedule I controlled substances, easing veterinary access to the drug. “This bill seeks to create an exemption for xylazine animal drug products for use by licensed veterinarians from the controlled substances FDA law,” bill sponsor Senator Joe Gruters said at the Senate Committee on Criminal Justice, explaining that his bill would not provide exceptions for human use of the drug. According to the bill’s analysis, a Schedule I drug has a “high potential for abuse” and “no currently accepted medical use.” The AVMA cautioned the federal government against classifying xylazine as such.

Click HERE to subscribe to the full Fountain Report content.